文献速递其他结缔组织病

自身抗体与硬皮病表型定义癌症高风险和低风险亚组

Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer.
PubMed 文献 · Ann Rheum Dis · 2018-04-20

在约翰霍普金斯硬皮病中心观察性队列的2383例患者中,分析不同自身抗体和表型亚组的癌症风险,并与美国SEER登记数据比较。结果显示,抗RNA聚合酶III抗体阳性者及缺乏着丝粒、拓扑异构酶-1和pol抗体者在硬皮病起病3年内癌症风险升高,而抗着丝粒抗体阳性者癌症风险降低。作者认为自身抗体特异性和疾病亚型可能有助于癌症风险分层,未来需研究靶向癌症筛查策略的价值。

要点

  • 抗RNA聚合酶III抗体阳性者硬皮病起病3年内癌症风险升高(SIR 2.84)。
  • 缺乏着丝粒、拓扑异构酶-1和pol抗体者癌症风险亦升高(SIR 1.83)。
  • 抗着丝粒抗体阳性者随访期间癌症风险降低(SIR 0.59)。

核心结论

  • 自身抗体特异性和疾病亚型是有生物学意义的筛选工具,可能有助于硬皮病患者的癌症风险分层。
  • 未来需要研究在硬皮病患者中检测靶向癌症筛查策略价值的工作。

研究设计与样本

  • 约翰霍普金斯硬皮病中心观察性队列研究,纳入2383例硬皮病患者,贡献37686人年。
  • 计算不同自身抗体和硬皮病表型亚组的总体及部位特异性癌症发病率,并与美国SEER登记数据比较。

主要发现

  • 205例患者(8.6%)诊断为癌症。
  • 硬皮病起病3年内,抗RNA聚合酶III抗体(antipol)阳性者癌症风险升高(SIR 2.84,95%CI 1.89至4.10)。
  • 硬皮病起病3年内,缺乏着丝粒、拓扑异构酶-1和pol抗体者癌症风险升高(SIR 1.83,95%CI 1.10至2.86)。
  • 在antipol阳性患者中,癌症特异性风险可能因硬皮病亚型而异;弥漫性硬皮病者乳腺癌风险升高,而局限性硬皮病者肺癌风险高。
  • 抗着丝粒抗体阳性者在随访期间癌症风险降低(SIR 0.59,95%CI 0.44至0.76)。

关键数值与推荐

  • 抗RNA聚合酶III抗体阳性者硬皮病起病3年内癌症风险SIR 2.84(95%CI 1.89至4.10)。
  • 缺乏着丝粒、拓扑异构酶-1和pol抗体者硬皮病起病3年内癌症风险SIR 1.83(95%CI 1.10至2.86)。
  • 抗着丝粒抗体阳性者随访期间癌症风险SIR 0.59(95%CI 0.44至0.76)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未来需要研究在硬皮病患者中检测靶向癌症筛查策略价值的工作。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Recent studies demonstrate autoantibodies are powerful tools to interrogate molecular events linking cancer and the development of autoimmunity in scleroderma. Investigating cancer risk in these biologically relevant subsets may provide an opportunity to develop personalised cancer screening guidelines. In this study, we examined cancer risk in distinct serologic and phenotypic scleroderma subsets and compared estimates with the general population. METHODS: Patients in the Johns Hopkins Scleroderma Center observational cohort were studied. Overall and site-specific cancer incidence was calculated in distinct autoantibody and scleroderma phenotypic subsets, and compared with the Surveillance, Epidemiology and End Results registry, a representative sample of the US population. RESULTS: 2383 patients with scleroderma contributing 37 686 person-years were studied. 205 patients (8.6%) had a diagnosis of cancer. Within 3 years of scleroderma onset, cancer risk was increased in patients with RNA polymerase III autoantibodies (antipol; standardised incidence ratio (SIR) 2.84, 95% CI 1.89 to 4.10) and those lacking centromere, topoisomerase-1 and pol antibodies (SIR 1.83, 95% CI 1.10 to 2.86). Among antipol-positive patients, cancer-specific risk may vary by scleroderma subtype; those with diffuse scleroderma had an increased breast cancer risk, whereas those with limited scleroderma had high lung cancer risk. In contrast, patients with anticentromere antibodies had a lower risk of cancer during follow-up (SIR 0.59, 95% CI 0.44 to 0.76). CONCLUSIONS: Autoantibody specificity and disease subtype are biologically meaningful filters that may inform cancer risk stratification in patients with scleroderma. Future research testing the value of targeted cancer screening strategies in patients with scleroderma is needed.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Igusa T, Hummers LK, Visvanathan K, et al. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis. 2018. PMID: 29678941. doi:10.1136/annrheumdis-2018-212999

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。